These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 38058226

  • 1. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
    Mizumachi K, Nakajima Y, Shimonishi N, Furukawa S, Ogiwara K, Takeyama M, Nogami K.
    Haemophilia; 2024 Jan; 30(1):140-150. PubMed ID: 38058226
    [Abstract] [Full Text] [Related]

  • 2. Anti-factor VIII inhibitor alloantibodies recognizing the A2 domain in the human factor VIII heavy chain poorly bind to porcine factor VIII.
    Sawamoto Y, Shima M, Tanaka I, Nakai H, Kamisue S, Scandella D, Yoshioka A.
    Int J Hematol; 1997 Feb; 65(2):151-8. PubMed ID: 9071819
    [Abstract] [Full Text] [Related]

  • 3. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
    Yada K, Nogami K, Shima M.
    Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
    [Abstract] [Full Text] [Related]

  • 4. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
    Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P.
    Blood; 2000 Jan 15; 95(2):564-8. PubMed ID: 10627463
    [Abstract] [Full Text] [Related]

  • 5. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE, Abajas YL, Wolberg AS, Nielsen BI, Marx GR, Baird CW, Neufeld EJ, Monahan PE.
    Haemophilia; 2017 Mar 15; 23(2):e93-e98. PubMed ID: 28124406
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect.
    Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, Shibata M, Saenko EL, Scandella D, Giddings JC, Yoshioka A.
    Br J Haematol; 1999 Oct 15; 107(1):196-203. PubMed ID: 10520041
    [Abstract] [Full Text] [Related]

  • 9. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H, Shima M, Arai M, Kagawa K, Fukutake K, Kamisue S, Nakai H, Morichika S, Tanaka I, Inoue M, Gale K, Tuddenham EG, Yoshioka A.
    Thromb Haemost; 1997 May 15; 77(5):862-7. PubMed ID: 9184393
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
    Ori J, Tanaka I, Kubota Y, Shima M, Matsumoto T, Yoshida K, Sakurai Y, Yoshioka A.
    Int J Hematol; 2005 Nov 15; 82(4):351-6. PubMed ID: 16298830
    [Abstract] [Full Text] [Related]

  • 12. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
    Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P.
    Thromb Haemost; 2009 Jul 15; 102(1):35-41. PubMed ID: 19572065
    [Abstract] [Full Text] [Related]

  • 13. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
    Négrier C, Oldenburg J, Kenet G, Meeks SL, Bordet JC, Müller J, Le Quellec S, Turecek PL, Tripkovic N, Dargaud Y.
    Res Pract Thromb Haemost; 2022 May 15; 6(4):e12731. PubMed ID: 35765670
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.
    Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P.
    J Biol Chem; 1997 Nov 28; 272(48):30191-5. PubMed ID: 9374501
    [Abstract] [Full Text] [Related]

  • 15. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M.
    J Thromb Haemost; 2015 Oct 28; 13(10):1843-53. PubMed ID: 26278069
    [Abstract] [Full Text] [Related]

  • 16. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC, Scott DW.
    Blood; 2005 Jun 15; 105(12):4865-70. PubMed ID: 15769892
    [Abstract] [Full Text] [Related]

  • 17. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII.
    Yada K, Nogami K, Ogiwara K, Shibata M, Shima M.
    Thromb Haemost; 2011 Jun 15; 105(6):989-98. PubMed ID: 21437361
    [Abstract] [Full Text] [Related]

  • 18. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.
    Lollar P, Parker ET.
    J Biol Chem; 1991 Jul 05; 266(19):12481-6. PubMed ID: 1905722
    [Abstract] [Full Text] [Related]

  • 19. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K.
    Thromb Haemost; 1996 Nov 05; 76(5):749-54. PubMed ID: 8950785
    [Abstract] [Full Text] [Related]

  • 20. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
    Mahlangu JN, Andreeva TA, Macfarlane DE, Walsh C, Key NS.
    Haemophilia; 2017 Jan 05; 23(1):33-41. PubMed ID: 27761964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.